Page 31 - Sofinnova Partners News Today

About MaxCyte MaxCyte is a world-leading provider of cell-engineering enabling technology and is responsible for helping to bring next-generation cell and gene-editing therapies to life. The Companys technology is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 140 cell therapy programmes, with more than 100 licensed for clinical use, and the Company has now entered into ...

Enthera Pharmaceuticals Extends Series A Financing, Raising a Total Of €35m Funds to be used to advance restorative therapy for type 1 diabetes and inflammatory bowel disease Largest international VC-backed Series A financing round for a biotech in Italy to date and first ever venture investment in an Italian company by both AbbVie Ventures and Roche Venture Fund Proceeds to be used for clinical proof-of-concept for lead product Ent001 (IGFBP3/TMEM219 inhibitor) for type 1 diabetes, gastroint...

Global: Early-stage healthcare funding focused on France and Africa Healthcare companies came out of the gates running in the first week of the year with early-stage healthcare funding focused on Europe and Africa. French medtech company CorWave has raised €35m (US$42.7m) in Series C funding. Existing shareholders Bpifrance, Novo Holdings, Seventure, Sofinnova Partners and Ysios Capital significantly increased their stake in the company and… You must be a HMI Subscriber to view this conten...

CorWave has raised $40 million to help with the development of its Left Ventricular Assist Device.

Novo Seeds Portfolio Company CorWave Raises EUR 35 Million for Breakthrough Heart Pump - Existing syndicate joined by the EIC Fund, a multi-billion-euro venture capital fund set up by the European Commission that becomes shareholder of a private company for the first time - Funding will accelerate development of wave membrane pump into heart failure clinical trials News provided by Share this article Share this article COPENHAGEN, Denmark, Jan. 6, 2021 /PRNewswire/ -- Novo Seeds, the early stag...

CorWave Raises $40 Million in Series C Funding for Its Breakthrough Heart Pump wave membrane pump. These new funds will enable CorWave to finalize development of its initial product, expand a manufacturing infrastructure, complete regulatory testing required to conduct human implants, and start its human clinical trials Bpifrance, Novo Holdings, Seventure, Sofinnova Partners and Ysios Capital, existing shareholders of CorWave who are leading investors in life sciences, significantly increased...

Published: Dec 21, 2020 Collaboration Strengthens Peijias Position for Competing in a Largely Untapped Market and Supports Global Expansion of HighLifes Technology SUZHOU, China and PARIS, Dec. 20, 2020 /PRNewswire/ -- Peijia Medical Ltd (HK Stock Code: 09996) and HighLife SAS, a Paris-based medical device company, focused on the development of a unique transeptal mitral valve replacement ("TMVR") system to treat patients suffering from mitral regurgitation, announced that they have enter...

21 dicembre 2020 Collaboration Strengthens Peijia’s Position for Competing in a Largely Untapped Market and Supports Global Expansion of HighLife’s Technology SUZHOU, China and PARIS, Dec. 21, 2020 /PRNewswire/ — Peijia Medical Ltd (HK Stock Code: 09996) and HighLife SAS, a Paris-based medical device company, focused on the development of a unique transeptal mitral valve replacement (“TMVR”) system to treat patients suffering from mitral regurgitation, announced that they have ent...

Noema Pharma AG, a Basel, Switzerland-based clinical-stage company targeting orphan neurological disorders, raised a Series A financing round, raising CHF54m ($59m USD). The round was co-led by Sofinnova Partners and Polaris Partners with participation from new international investors Gilde Healthcare, Invus and BioMed Partners. Roche, the Swiss multinational healthcare company, received a shareholding in Noema in exchange for rights to four clinical-stage product-candidates. In conjunction wi...

Share this article Share this article Seven start-up companies and university research projects across a range of therapeutic areas and geographical locations form latest intake for life science incubator BioInnovation Institute COPENHAGEN, Denmark, Dec. 2, 2020 /PRNewswire/ -- BioInnovation Institute (BII), a Novo Nordisk Foundation initiative incubating and accelerating world-class life science research, today identifies its latest cohort of program participants. Comprising a pan-European sp...